



Cairo University
Faculty of Veterinary Medicine
Dept. of Biochemistry and Chemistry of Nutrition

Some Biochemical Studies on Immune Response of Chronic Kidney Disease Patients

Presented By

Samar Kamel Mohamed Khalil

B. V. Sc., Cairo University (2003)

M.V.Sc., Cairo University (2010)

**For the degree of Ph.D. in Veterinary Sciences
(Biochemistry and Chemistry of Nutrition)**

Under the supervision of

Prof. Dr. Hassan Abd EL-Halim H. Amer

Professor of Biochemistry and Chemistry of Nutrition

Faculty of Veterinary Medicine - Cairo University

Prof. Dr. Adel M. El-Behairy

Professor of Biochemistry and
Chemistry of Nutrition
Faculty of Veterinary Med.,
Cairo University

Prof. Dr. Mohamad Ali Warda

Professor of Biochemistry and
Chemistry of Nutrition
Faculty of Veterinary Med.,
Cairo University

Dr. Mohamad H. Shahin

Head of Laboratory Medicine Dept.
Maadi Armed Forces Hospital

(2016)

Approval sheet

This is approved that the dissertation by Vet. Dr. **Samar Kamel Mohamed Khalil** to Cairo University for the Degree of Ph.D. in Veterinary Science (Biochemistry and Chemistry of Nutrition) has been approved by the examining committee.

Prof. Dr. Mohamed Ahmed Kandel

Professor and Head of Biochemistry and
Chemistry of Nutrition Department
Faculty of Vet. Medicine- Beni Suef University



Prof. Dr. El Said Thabet Awad

Professor of Biochemistry and Chemistry of Nutrition
Faculty of Veterinary Medicine - Cairo University




Prof. Dr. Hassan Abd EL-Halim H. Amer

Professor of Biochemistry and Chemistry of Nutrition
Faculty of Veterinary Medicine - Cairo University



Prof. Dr. Adel Mohamed A. El-Behairy

Professor of Biochemistry and Chemistry of Nutrition
Faculty of Veterinary Medicine - Cairo University



Prof. Dr. Mohamed Ali Ahmed Warda

Professor of Biochemistry and Chemistry of Nutrition
Faculty of Veterinary Medicine - Cairo University



Cairo University
Faculty of Veterinary Medicine
Dept. of Biochemistry and Chemistry of Nutrition

Supervision Sheet

Supervisors

Prof. Dr. Hassan Abd EL-Halim H. Amer

Professor of Biochemistry and Chemistry of Nutrition
Faculty of Veterinary Medicine - Cairo University

Prof. Dr. Adel M. Abo El-Fetouh El-Bhairy

Professor of Biochemistry and Chemistry of Nutrition
Faculty of Veterinary Medicine - Cairo University

Prof. Dr. Mohamad Ali A. Warda

Professor of Biochemistry and Chemistry of Nutrition
Faculty of Veterinary Medicine - Cairo University

Dr. Mohamad Hassan Shahin

Head of Laboratory Medicine Dept.
Maadi Armed Forces Hospital

Cairo University
Faculty of Veterinary Medicine
Dept. of Biochemistry and Chemistry of Nutrition

Name : Samar Kamel Mohamed Khalil
Nationality : Egyptian
Date of birth : 8 / 6/ 1980
Place of birth : Cairo
Specification : Dept. of Biochemistry and Chemistry of Nutrition
Thesis title : "Some Biochemical Studies on Immune Response of Chronic Kidney Disease Patients".
Supervisors : Prof. Dr. Hassan Abd EL-Halim H. Amer
Prof. Dr. Adel Mohamad A. El-Behairy
Prof. Dr. Mohamad Ali A. Warda
Dr. Mohamad Hassan Shahin

Abstract

Inflammation and oxidative stress are two faces of one coin in end stage renal disease patients (ESRD) on maintenance hemodialysis. Their interconnection induces anemia complicated with erythropoietin hyporesponsiveness. The biochemical basis behind the resistance to erythropoietin therapy with frequent hemoglobinemia, oxidative stress and iron status have not been fully recovered. Two equal groups (40 patients each) of responders and non-responders to recombinant human erythropoietin therapy (higher than 300 IU /kg/wk of epoetin) were used in the study. Hematological and biochemical analysis of collecting blood and serum samples were performed along with serum electrophoretic protein foot printing. The leukocytes DNA fragmentation was used to evaluate the degree of oxidative insult. Erythropoietin (EPO) good responders showed lower erythrocyte malondialdehyde (E-MDA) level; less pronounced DNA fragmentation of circulating leukocytes than poor responder with elevated hemoglobin, albumin, A/G ratio, total iron, and ferritin levels. Contrariwise, lower erythrocyte superoxide dismutase (E-SOD) and catalase activities in EPO poor responder group than good responder one. Other serum constituents and electrophoretic protein pattern showed a no significant difference between the two groups. There were higher levels of inflammatory markers, interleukin-6 (IL-6) and C- reactive protein (CRP) in EPO poor responder than good responder. The present data showed negative correlations between Hb with both IL-6 and CRP levels, indicating a positive correlation between inflammatory markers and severity of anemia. A direct correlation between Hb and antioxidant enzymes (E-SOD and catalase) was noticed, while the inverse correlation with E-MDA was recorded.

Key words: erythropoietin resistance; inflammatory markers; oxidative stress; hemodialysis; anemia of chronic disease.

DEDICATION

To The sole of my father

& the sole of the Eldest Brother' Mustafa'

To My loving & caring Mother

To My Beloved Brother 'Mohamad'

& My Dear Sisters "5N"

ACKNOWLEDGMENT

*Firstly and for most, my deepest thanks to **Allah** who gives us everything and showing us the right path.*

*I would like to express my deep gratitude to my supervisor **Prof. Dr. Hassan Abd EL-Halim Amer**, Professor of Biochemistry and Chemistry of Nutrition, Faculty of Vet. Med., Cairo University, for his supervising, and planning of the work,*

*I would like to express my great thanks to **Prof. Dr. Adel M. Abo EL-Fetouh El Behairy**, Professor of Biochemistry and Chemistry of Nutrition, Faculty of Vet. Med., Cairo University, for great help, cooperation, and support during the course of this work,*

*I have no adequate words to express my gratitude for the close supervision, guidance, active participation, valuable advice, and kind encouragement of **Prof. Dr. Mohamad Ali A. Warda**, Professor of Biochemistry and Chemistry of Nutrition, Faculty of Vet. Med., Cairo University.*

*I would like to thank **Dr. Mohamad Hassan Shaheen**, head of Laboratory Medicine Department, Maadi Armed Forces Hospital, for his valuable criticism.*

*My thanks extended to **Prof. Dr. Nadia A. El Tablawy** for her kind advice and help.*

I would like also to thank all members of Biochemistry and Chemistry of Nutrition department, Faculty of Vet. Med., Cairo University for their support in this work,

*Finally, but not least, I would like to thank my **family & friends** for their endless love, trust, encouragement, and support throughout my life.*

CONTENTS

| | Page |
|---|-----------|
| 1. INTRODUCTION..... | 1 |
| 2. REVIEW OF LITERATURE..... | 6 |
| 2.1. Classification of CKD Patients according to GFR..... | 6 |
| 2.2. Comorbid conditions and Complications in patients with CKD..... | 7 |
| 2.2.1. Biochemical alterations of blood parameters in CKD... | 7 |
| 2.2.1.1. Uremia | 7 |
| 2.2.1.2. Hyperuricemia | 9 |
| 2.2.1.3. Hypoalbuminaemia | 10 |
| 2.2.1.4. Electrolyte imbalance | 11 |
| 2.2.1.5. Disturbances of calcium and phosphorus metabolism..... | 12 |
| 2.2.1.6. Hyperlipidemia | 12 |
| 2.2.2. Anemia..... | 14 |
| 2.3. Anemia of Chronic diseases..... | 15 |
| 2.3.1. How kidney failure leads to anemia?. | 15 |
| 2.3.1.1. Erythropoietin deficiency..... | 16 |
| 2.3.1.2. Iron deficiency..... | 18 |
| 2.3.1.3. Inflammation and oxidative stress..... | 22 |
| 2.3.1.4. Blood loss..... | 25 |
| 2.3.1.5. Uremic milieu | 25 |
| 2.4. Treatment of Anemia | 26 |
| 2.4.1. Erythropoietin..... | 27 |

| | |
|---|-----------|
| 2.4.2. ESAs dosing and Administration | 29 |
| 2.5- ESAs hyporesponsiveness..... | 30 |
| 2.5.1. Inflammation and Inflammatory Markers in ESRD patients on maintenance HD..... | 31 |
| 2.5.1.1. C-reactive protein..... | 33 |
| 2.5.1.2. Interleukin 6 | 36 |
| 2.5.2. Oxidative Stress | 39 |
| 2.5.2.1. Oxidative Stress Markers..... | 42 |
| 2.5.2.1.1. Malondialdehyde (MDA) | 44 |
| 2.5.2.1.2. DNA fragmentation | 45 |
| 2.5.2.1.3. Superoxide dismutases | 46 |
| 2.5.2.1.4. Catalase activity | 48 |
| 2.5.3. Malnutrition..... | 49 |
| 2.5.4. Chronic blood loss | 50 |
| 2.5.5. Hyperparathyroidism..... | 50 |
| 2.5.6. Iron deficiency | 52 |
| 2.5.7. Aluminum toxicity..... | 54 |
| 2.5.8. Anti-erythropoietin antibodies | 54 |
| 2.5.9. Inadequate dialysis | 55 |
| 3. SUBJECTS AND METHOD..... | 56 |
| 3.1. Subjects..... | 56 |
| 3.2. Experimental design..... | 56 |
| 3.3. Exclusion criteria..... | 57 |
| 3.4. Blood samples..... | 57 |
| 3.5. Complete blood count..... | 59 |
| 3.6. Determination of PTH level..... | 59 |

| | |
|--|-----------|
| 3.7. Methods used for determination of oxidative stress and antioxidant parameters..... | 61 |
| 3.7.1. Determination of E-MDA..... | 61 |
| 3.7.2. DNA-fragmentation assay..... | 63 |
| 3.7.3. Determination of E-SOD..... | 66 |
| 3.7.4. Estimation of catalase activity..... | 68 |
| 3.8. Determination of Plasma osmolality level..... | 69 |
| 3.9. Methods used for determination of Biochemical parameters..... | 70 |
| 3.9.1. Determination of blood urea nitrogen..... | 70 |
| 3.9.2. Determination of serum creatinine..... | 71 |
| 3.9.3. Determination of serum uric acid..... | 71 |
| 3.9.4. Determination of serum iron level..... | 72 |
| 3.9.5. Determination of serum calcium level..... | 72 |
| 3.9.6. Determination of serum phosphorus..... | 73 |
| 3.9.7-Determination of serum total proteins..... | 73 |
| 3.9.8-Determination of serum albumin..... | 74 |
| 3.9.9-Determination of serum globulin..... | 74 |
| 3.9.10-Determination of A/G ratio..... | 74 |
| 3.9.11. Determination of total bilirubin..... | 75 |
| 3.9.12. Determination of Alanine aminotransferase..... | 75 |
| 3.9.13. Determination of Aspartate aminotransferase..... | 76 |
| 3.9.14. Determination of Alkaline phosphatase..... | 76 |
| 3.9.15. Determination of Total Cholesterol level..... | 77 |
| 3.9.16. Determination of Triacylglycerol..... | 78 |
| 3.9.17. Determination of blood glucose level..... | 79 |

| | |
|--|------------|
| 3.10. Determination of Electrolytes..... | 79 |
| 3.11. Determination of serum ferritin level..... | 80 |
| 3.12. Methods used for determination of inflammatory markers..... | 81 |
| 3.12.1. Determination of IL-6..... | 81 |
| 3.12.2. Determination of CRP..... | 85 |
| 3.13. Methods used for protein pattern analysis..... | 87 |
| 3.14. Statistical analysis..... | 92 |
| 4. RESULTS..... | 93 |
| 5. DISCUSSION..... | 109 |
| 6. CONCLUSION..... | 135 |
| 7. SUMMARY..... | 136 |
| 8. REFERENCES..... | 140 |
| 9. ARABIC SUMMARY..... | 172 |

LIST OF TABLES

- Table (1):** Pre HD levels of kidney functions, minerals, plasma osmolality and related electrolytes of EPO poor responder and good responder ESRD patients
- Table (2):** Pre HD levels of liver functions and protein profile of EPO poor responder and good responder ESRD patients
- Table (3):** Pre HD levels of blood glucose and lipids of EPO poor responder and good responder ESRD patients
- Table (4):** Pre HD levels of haemoglobin, total iron, ferritin and PTH in EPO poor responder and good responder ESRD patients
- Table (5):** Pre and Post HD levels of inflammatory markers (IL6 and CRP) in serum of EPO poor responder and good responder ESRD patients
- Table (6):** Pre HD levels of E-MDA and E-SOD in EPO poor responder and good responder ESRD patients
- Table (7):** Correlations between Hb level and other parameters
- Table (8):** Inter correlations between other parameters

LIST OF FIGURES

- Figure (1):** Pre HD levels of Protein Profile
- Figure (2):** Pre HD levels of blood glucose and lipids
- Figure (3):** Pre HD levels of total iron, ferritin and PTH
- Figure (4):** Pre and Post HD levels of IL- 6
- Figure (5):** Pre and Post HD levels of CRP
- Figure (6):** Catalase activity
- Figure (7):** Electrophoretic pattern of DNA fragmentation assay
- Figure (8):** Protein foot printing in control and ESRD patients (poor and good responders to EPO)

Introduction

The 'uremic milieu' is a term that is overused in attempts to explain the multiple organ dysfunction of chronic kidney disease (CKD). In vivo, the concept of a uremic milieu may explain why the level and prevalence of anemia correlate with the severity of the kidney disease. A glomerular filtration rate (GFR) lower than 60 mL/minute/1.73 m² has been associated with a higher prevalence of anemia, which reached 75% in some studies (McClellan *et al.*, 2004).

O'Mara, (2008) defined anemia in patients with chronic renal failure according to age and sex as an hemoglobin (Hb) concentration of < 11.5 g/dl in women, < 13.5 g/dl in men ≤ 70 years of age, and < 12 g/dl in men > 70 years of age.

Renal anemia has been regarded as a special form of 'anemia of chronic disease' (ACD), in which inappropriate levels of erythropoietin (EPO) is considered as the main cause (Zarychanski and Houston, 2008). McClellan *et al.*, (2004) postulated that the specialized peritubular cells that produce EPO are partially or completely depleted or injured as renal disease progresses.

Anemia is universal in CKD primarily due to a relative lack of EPO. Various secondary causes can contribute to anemia, including a deficiency of iron, gastrointestinal bleeding, active blood loss; haemolysis; haemo-globinopathies; aluminum overload; hypothyroidism; severe hyperparathyroidism (elevated parathyroid

hormone (PTH) concentrations); inflammatory conditions (acute and chronic inflammations suppress erythropoiesis in the bone marrow); shortened red blood cells (RBCs) survival due to uremia, and deficiencies of folate and vitamin B12 (**Dowling *et al.*, 2007**).

Abu-Alfa, (2003) has reported that iron deficiency is a common secondary cause of anemia in CKD, and several factors may contribute to the development and maintenance of this deficiency.

Hemodialysis (HD) patients lose 2 gram of iron per year due to blood trapping in dialyzers, repeated phlebotomy and gastrointestinal losses. This amount corresponds to the iron that normally is absorbed in 1000-2000 days and to more than the half of the total body iron (**Eleftheriadis *et al.*, 2009**).

Resistance to erythropoiesis stimulating agents (ESAs) has been associated with an increased risk of cardiovascular events and death in CKD patients (**Solomon *et al.*, 2010**). In the same way, **Panichi *et al.*, (2011)** stated that ESAs response reflects the overall health status of the patient and indeed, high ESAs resistance is associated with increased morbidity and mortality.

Although the majority of CKD patients respond adequately to ESAs, 10% of these patients does not adequately respond to the recombinant human erythropoietin (rhEPO) therapy and show a marked resistance to this therapy (**Bárány, 2001** and **Smrzova *et al.*, 2005**).

Additionally, **Cooper *et al.*, (2003)** and **Smrzova *et al.*, (2005)** demonstrated that the reasons for this variability of rhEPO response are unclear. There are a lot of conditions associated with rhEPO resistance, including inflammation, oxidative stress and iron deficiency, as major causes, and blood loss, hyperparathyroidism, aluminium toxicity and vitamin B12 or folate deficiency, as minor causes. However, exclusion of these factors does not eliminate the marked variability in sensitivity to rhEPO (**Macdougall and Cooper, 2002**).

Several studies reported on levels of lipid peroxidation and antioxidants in HD patients with variable results due to different factors such as dialysis materials (e.g., the kind of HD membrane) (**Malliaraki *et al.*, 2003**), duration of HD therapy (**Nguyen-Khoa *et al.*, 2001**) and **Ferretti *et al.*, 2008**) and trace elements disturbances.

Inflammatory markers are powerful predictors of mortality after adjustment for other risk factors (**Panichi *et al.*, 2004**). Inflammation also is responsible for other mortality risk factors, such as anemia, malnutrition, vascular disease, and left ventricular hypertrophy.

Interleukin 6 (IL-6) probably is more related to mortality and is associated with more causes of inflammation than C- reactive protein (CRP) (**Panichi *et al.*, 2004**).

Patients with end stage renal disease (ESRD) undergoing renal replacement therapy, either hemodialysis or peritoneal dialysis (PD), may face a partial loss of some low molecular- weight plasma factors